APC
BTAI icon

Aspire Private Capital’s BioXcel Therapeutics BTAI Stock Holding History

Aspire Private Capital’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed -$1K – 615
2022
Q2 		$1K Hold
6
– – ﹤0.01% 528
2022
Q1 		$2K Hold
6
– – ﹤0.01% 486
2021
Q4 		$2K Hold
6
– – ﹤0.01% 507
2021
Q3 		$3K Hold
6
– – ﹤0.01% 436
2021
Q2 		$3K Buy
+6
New +$3.27K ﹤0.01% 445

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aspire Private Capital's BTAI Position: Q3 2022 in Review

Aspire Private Capital sold out of BioXcel Therapeutics (BTAI) in Q3 2022, closing a stake of 6 shares — an estimated $1K sold.

Aspire Private Capital first reported a position in BTAI in Q2 2021 and held it in 5 quarters. The position peaked at $3K in Q3 2021. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2022.

  • Aspire Private Capital reported no remaining BioXcel Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Aspire Private Capital sold 6 BioXcel Therapeutics shares in Q3 2022, an estimated $1K.
  • Aspire Private Capital first reported a position in BioXcel Therapeutics in Q2 2021 and held it in 5 quarters.
  • Aspire Private Capital's BioXcel Therapeutics position peaked at $3K in Q3 2021.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2022.

Based on Aspire Private Capital's 13F filing for Q3 2022, filed 10 Nov 2022.